Navigation Links
Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
Date:2/28/2008

Nordic Biotech II K/S and MPM BioVentures close on additional $6 million

investment on top of $75 million previous investment

AMSTERDAM, Netherlands and ALAMEDA, Calif., Feb. 28 /PRNewswire/ -- Arriva Pharmaceuticals, a biopharmaceutical company focused on developing anti- inflammatory therapies for treating respiratory diseases, completed a financing of 6 million USD led by new Investor Nordic Biotech II K/S and with participation by MPM BioVentures. Since its founding in 1997, Arriva has now raised a total of 81 million USD.

"Key financing from Nordic Biotech II KS and from our earlier lead investor, MPM Capital, allows us to continue the development of recombinant alpha-one antitrypsin for hereditary emphysema," said Sue Preston, CEO, Arriva Pharmaceuticals. "With a committed, experienced management team, we are now focused on the clinical development of our lead and pipeline products."

"We are investing in the clear value we see in Arriva's late-stage inhaled protein rAAT, a replacement product for the treatment of hereditary emphysema," said Florian Schonharting, partner of Nordic Biotech. "Our goal with Arriva is to provide financing and through board participation, help the company become a recognized, fully integrated biotech concern," added Christian Hansen, partner of Nordic Biotech.

"MPM has been a supporter of Arriva and the company's mission since 2002," said Ansbert Gadicke, General Partner, MPM Capital. "We continue to believe that there is significant potential in the company's respiratory product pipeline and are involved in this financing because we anticipate that Arriva will successfully capitalize on its IP and other assets."

About Arriva:

Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, chronic obstructive pulmonar
'/>"/>

SOURCE Arriva Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MOUNTAIN VIEW, Calif. , July 24, 2014 ... ), a leading provider of medication and supply ... hold a conference call Thursday, July 31, to ... What:  , Omnicell Second Quarter 2014 earnings ... 2014, 1:30 p.m. PTWho:  , Randall Lipps, chairman, ...
(Date:7/24/2014)... (NYSE MKT: IG), a New Jersey based specialty generic drug ... second quarter ended June 30, 2014. Second Quarter ... in the second quarter of 2014, an increase of 70% ... of $13.3 million for the six months ended June 30, ... 2013 , Total revenues generated from the sale of ...
(Date:7/24/2014)... , July 24, 2014 Many new dentists ... can do to ensure that their practice will be a ... the basic supplies they use the most can make all ... many dentists have recently discovered that purchasing discount dental ... According to successful dentists across ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Dental Supplies Online is Key to Dental Success...Really! 2
... study shows ACTEMRA is first and only biologic to, demonstrate ... ... treatment -, PARIS, June 13 ... -- despite treatment with,current therapies -- achieved significant improvements in signs ...
... France, June 13 , NicOx S.A. (Euronext ... blood pressure data from the 301 phase 3 ... naproxen in,terms of the mean change from baseline ... (p<0.05 for 3 out of 4 comparisons). Commonly ...
Cached Medicine Technology:ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 2ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 3ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 4ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 5ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 6ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies 7NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR 2NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR 3NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR 4
(Date:7/24/2014)... July 24, 2014 CarePoint Health ... in hematology and oncology, Dr. Hitendra Upadhyaya, has ... system welcomes Dr. Upadhyaya to the community. Hundreds ... Health Medical Group, a comprehensive network of top ... wide range of specialties. This latest acquisition represents ...
(Date:7/24/2014)... Pools and beaches are the place to be on ... for small children, so Amica Insurance is sharing ... Centers for Disease Control and Prevention, children between the ages ... injuries and deaths. It’s important to know the best practices ... offering the following tips from the American Red Cross:, ...
(Date:7/24/2014)... This year the Walk to End Alzheimer’s in ... Life, will be held on Saturday, September 20 in Denver ... Run at 7:50 am, the untimed 5k Run at 8 ... Walk to End Alzheimer’s unites the entire community in a ... this devastating disease, “stated Linda Mitchell, CEO and president of ...
(Date:7/24/2014)... a foreign material like a medical device or surgical ... always responds. According to Northwestern University,s Guillermo Ameer, most ... affect the device,s function. , "You will always get ... of biomedical engineering in Northwestern,s McCormick School of Engineering ... Feinberg School of Medicine. "A problem with commonly used ...
(Date:7/24/2014)... Researchers at Le Bonheur Children,s Hospital and the ... a clinical trial of a new drug shown to ... healthy adult volunteers intranasally infected with respiratory syncytial virus ... respiratory tract infections in young children in the United ... the labs of Infectious Disease Specialist John DeVincenzo, MD. ...
Breaking Medicine News(10 mins):Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3Health News:Antioxidant biomaterial promotes healing 2Health News:RSV research breakthrough to help infected children 2
... 4 Nu Skin Enterprises, Inc. (NYSE: NUS ... quarterly dividend of $0.115 per share, which will be paid ... 15, 2009. , , The Company , ... its tradition of innovation through its comprehensive anti-aging product portfolio, ...
... planned benefit changes , , PORTLAND, Ore., June 4 ... perfect storm of rising health care costs and the declining ... three years of predictable rate adjustments and planned benefit changes, ... economic uncertainties. , , In these trying ...
... DIEGO, June 4 NuVasive, Inc. (Nasdaq: NUVA ... minimally disruptive surgical treatments for the spine, announced today that ... to present at the 8th Annual Needham Life Sciences Conference ... York, on Thursday, June 11, 2009, at 11:00 a.m. Eastern ...
... violent relationship may lead to poor mental health, ... --Adults who witnessed parental violence while growing up ... according to researchers who studied 3,023 adults in ... current depression, as well as their experiences with ...
... - , , - Total Net Sales in Line with Previous ... Today at 3:30 pm Central Time - , ... a medical device company that develops, manufactures and markets innovative proprietary products ... and full year ended March 31, 2009. Net sales of $2.9 ...
... is proud to announce the four finalists for its ... a competition to find Minnesota,s most innovative and effective ... cash awards as part of the Engaged Philanthropy Conference ... Graves 601 Hotel in Minneapolis. The Social Entrepreneur,s Cup ...
Cached Medicine News:Health News:Regence Rate Assure(SM) Offers Employer Groups Guaranteed Rates, Benefits 2Health News:NuVasive to Present at the 8th Annual Needham Life Sciences Conference 2Health News:NuVasive to Present at the 8th Annual Needham Life Sciences Conference 3Health News:When Parents Fight, Children Often End Up With Scars 2Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 2Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 3Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 4Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 5Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 6Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 7Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 8Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 9Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 10Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 11Health News:Social Entrepreneur's Cup Finalists Announced 2Health News:Social Entrepreneur's Cup Finalists Announced 3Health News:Social Entrepreneur's Cup Finalists Announced 4Health News:Social Entrepreneur's Cup Finalists Announced 5
... Raintree Billing Manager and Collections ... centralized or de-centralized billing models and ... collection ratios with the ability to ... single claims more directly from the ...
Visionary OFFICE™ PM offers a Windows interface featuring medical billing, appointment scheduling and patient information....
A.I.med's medical billing software is a medical billing software. The billing module integrates with A.I.med's Electronic Medical Record software. A.I.med's medical billing module also integrates wit...
... system allows a practice to manage ... integrated with the EMR, appointment system ... with electronic clearinghouses for electronic claim ... of reports, it presents practice management ...
Medicine Products: